![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, November 09, 2012 6:05:02 PM
Just to preface....I am a physician and have extensive knowledge of medicine and some background in organic chemistry and bio-chem....but by no means a specialist in chemistry or laws surrounding NCE. I have been on the edge to sell my shares because previously I was pretty sure that we would not get the NCE...but this is what I just found after weeks of research...
the proof is all in he labels, look at loveza and vascepa:
-loveza is a mixture of EPA cis and trans isomers + DHA. For those that don't know what an isomer is, they same chemical makeup....but MIRROR IMAGES of each other. The common argument on here is that " Vascepa is pure EPA, without the DHA and so we should get NCE." By strict definition of the FDA, this will not get us NCE. But we will get it and I will tell you why...once again it is all in the label
- Vascepa is ethyl all-cis-5,8,11,14,17-icosapentaenoate (CC'd directly from the label). This is the trans MIRROR IMAGE. Remember, lovveza is a mixture of cis and trans........
THIS IS WHY WE WILL GET NCE (and before I found this an hour ago, I thought it would not get NCE)
** Joe Z. was very smart when he developed this drug. He knew the FDA NCE statues I will copy and paste below and he knew that if he used both isomers of EPA he would not get NCE. But he isolated the cis isomer of EPA....this is one of his guarded trade secrets, as isomers are not easy to separate!
By doing this as seen below it qualifies for NCE. I am sure quite a bit of money was spent separating these isomers, it would have been simplier and much less costly to just use the racemic mixture. So why didn't he use the racemic mixture.....it would save bundles of $$$$$$?
Because in 1997 the FDA passed the FDA Revitalization Act "FDARA". There is ABSOLUTELY no other reason to seperate them and use only the cis isomer in Vascepa, it is just not cost effective. You see, the FDARA 264 in 1997 replaced the Hatch-Waxman Act which originally said ' FDA will consider wether a drug contains a previously approved active moiety on a case-by-case basis. FDA notes that a single enantiomer of a previously approved active moiety and is therefore not considered a new chemical entity.'
Because of FDARA 264 this is how it currently stands:
**Here is the direct quote from the FDA below (FDARA 264), this addendum to the Hatch-Waxman Act
specifically....FDARA 264 amended FDC Act to add 505(t)--"certain drugs containing single enantiomers"--to provide that:
...if an application is submitted under 505 (b) for such non-racemic drug containing as an active ingredient a single enantiomer that is contained in a racemic drug approved in another application under 505(b), the applicant may, in the application for such non-racemic drug, elect to have the single enantiomer not be considered the same active ingredient as that contained in the approved racemic drug.....
Thus, if a single enantiomer is not considered to be the same active ingredient as that contained , FDA may consider it to be a new chemical entitiy eligible for 5 year exclusivity!!!!!
Here is the best part....if you google fdara 264 and pull up the law book and sec 264, this expires oct 1st 2012 unless congress reauthorizes it. "application must be submitted between date of enactment and oct 1 2012'....want to guess why Joe Z. wanted to push the NCE application through in August (which he did)....
The senate passed this FDARA provision in order to put to bed a 1997 FDA notice in which the Agency requested comment on whether granting a 5 year period of exclusivity to enantiomers of previously approved racemates would encourage medically significant innovation.
Good luck, and I hope you make lots of money.......
Recent AMRN News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
FEATURED Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • Jun 14, 2024 2:07 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM